Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. As Pascale Davies reports, the deal suggests there is value locked up within Shire's portfolio - despite a dismal share price performance in the past two years.
With "My Queue" you can quickly save videos to watch later.
To add an item to your queue just click the sign next to the video.
Once you've added a video visit "My Queue" to start watching!